| Literature DB >> 27713564 |
Xiaoyue Wang1, Yang Liu1, Lili Wang1, Jianping Han1, Shilin Chen2.
Abstract
It is very difficult to identify Angelicae sinensis radix (Danggui) when it is processed into Chinese patent medicines. The proposed internal transcribed spacer 2 (ITS2) is not sufficient to resolve heavily processed materials. Therefore, a short barcode for the identification of processed materials is urgently needed. In this study, 265 samples of Angelicae sinensis radix and adulterants were collected. The ITS2 region was sequenced, and based on one single nucleotide polymorphism(SNP) site unique to Angelica sinensis, a nucleotide signature consisting of 37-bp (5'-aatccgcgtc atcttagtga gctcaaggac ccttagg-3') was developed. It is highly conserved and specific within Angelica sinensis while divergent among other species. Then, we designed primers (DG01F/DG01R) to amplify the nucleotide signature region from processed materials. 15 samples procured online were analysed. By seeking the signature, we found that 7 of them were counterfeits. 28 batches of Chinese patent medicines containing Danggui were amplified. 19 of them were found to contain the signature, and adulterants such as Ligusticum sinense, Notopterygium incisum, Angelica decursiva and Angelica gigas were detected in other batches. Thus, this nucleotide signature, with only 37-bp, will broaden the application of DNA barcoding to identify the components in decoctions, Chinese patent medicines and other products with degraded DNA.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27713564 PMCID: PMC5054691 DOI: 10.1038/srep34940
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The alignment of the 37-nucleotide conserved region.
Figure 2Two primer pairs amplify different sizes of sequences from decoctions and extract powder.
Note: Except for the first and last lanes (marker), the remaining 12 lanes are divided into two groups for two primer pairs. Each primer pair occupies six lanes. Lanes from left to right are DG01F/DG01R and ITS2F/3R. The first lane in each primer pair (lane 1 and 7) is a negative control. The second lane (lane 2 and 8) is a positive control without boiling. The third to fifth lanes (lane 3, 4, 5, 9, 10 and 11) are PCR products from decoctions with boiling times of 120 min, 180 min and 240 min, respectively. The sixth lane (lane 6 and 12) is a PCR product from extract powder.
Characteristics of the A. sinensis samples used in the study.
| Sample No. | Latin Name of Original Species | Latin Name of Medicinal Materials | Sample Type | Collection Site | Collection Approach | Identification Result |
|---|---|---|---|---|---|---|
| DGF01 | Angelicae sinensis radix | Powder | Anhui Bozhou Herb Market | Online | ||
| DGF03 | Angelicae sinensis radix | Powder | Anhui Bozhou Herb Market | Online | ||
| DGF04 | Angelicae sinensis radix | Powder | Anhui Bozhou Herb Market | Online | ||
| DGF05 | Angelicae sinensis radix | Powder | Anhui Bozhou Herb Market | Online | ||
| DGF06 | Angelicae sinensis radix | Powder | Anhui Bozhou Herb Market | Online | ||
| DGF07 | Angelicae sinensis radix | Powder | Anhui Bozhou Herb Market | Online | ||
| DGF08 | Angelicae sinensis radix | Powder | Anhui Bozhou Herb Market | Online | ||
| DGF02 | Angelicae sinensis radix | Powder | Anhui Bozhou Herb Market | Online | ||
| DGF09 | Angelicae sinensis radix | Powder | Dingxi, Gansu | Online | ||
| DGT01 | Angelicae sinensis radix | Extract Powder | Xi’an, Shaanxi | Online | ||
| DG02 | Angelicae sinensis radix | Medicinal slices | Dingxi, Gansu | Online | ||
| DG03 | Angelicae sinensis radix | Whole Radix | Dingxi, Gansu | Online | ||
| DG04 | Angelicae sinensis radix | Whole Radix | Chengdu, Sichuan | Online | ||
| DG05 | Angelicae sinensis radix | Medicinal slices | Heze, Shandong | Online | ||
| DG06 | Angelicae sinensis radix | Medicinal slices | Dingxi, Gansu | Online |
Characteristics of the 28 Chinese patent medicines.
| Sample Order | Sample NO. | Sample Name | Collection Site | Amplication Result | Related species in Identification Result |
|---|---|---|---|---|---|
| 1 | ZCY1 | Huoxue Zhitong Capsule | Beijing store | Clean traces | |
| 2 | ZCY2 | Tianwang Buxin Pill | Beijing store | Clean traces | |
| 3 | ZCY3 | Renshen Yangrong Pill | Beijing store | Clean traces | |
| 4 | ZCY4 | Renshen Zaizao Pill | Beijing store | Clean traces | |
| 5 | ZCY5 | Guipi Pill | Beijing store | Clean traces | |
| 6 | ZCY6 | Shenrong Baotai Pill | Beijing store | Clean traces | |
| 7 | ZCY7 | Dingkun Pill | Beijing store | Overlapping traces | |
| 8 | ZCY9 | Wuji Baifeng Pill | Beijing store | Overlapping traces | |
| 9 | ZCY10 | Niuhuang Qingxin Pill | Beijing store | Overlapping traces | |
| 10 | ZCY11 | Wuji Baifeng Pill | Beijing store | Clean traces | |
| 11 | ZCY12 | Huoxue Zhitong Capsule | Beijing store | Clean traces | |
| 12 | ZCY13 | Renshen Jianpi Pill | Beijing store | Clean traces | |
| 13 | ZCY14 | Niuhuang Qingxin Pill | Beijing store | Overlapping traces | |
| 14 | ZCY15 | Buzhong Yiqi Pill | Beijing store | None | - |
| 15 | ZCY17 | Guipi Pill | Guangdong store | Overlapping traces | |
| 16 | ZCY18 | Wuji Baifeng Pill | Guangdong store | Overlapping traces | |
| 17 | ZCY19 | Huoxue Tongluo Capsule | Guangdong store | None | - |
| 18 | ZCY20 | Qixue Shuangbu Pill | Beijing store | Clean traces | |
| 19 | ZCY21 | Baihe Gujin Pill | Beijing store | Clean traces | |
| 20 | ZCY22 | Duhuo Jisheng Pill | Beijing store | Overlapping traces | |
| 21 | ZCY23 | Pishen Liangzhu Pill | Beijing store | Clean traces | |
| 22 | ZCY24 | Qiangli Tianma Duzhong Capsule | Beijing store | Clean traces | |
| 23 | ZCY25 | Buzhong Yiqi Pill | Beijing store | Clean traces | |
| 24 | RSJ01 | Renshen Jianpi Pill | Beijing store | Clean traces | |
| 25 | RSJ02 | Renshen Jianpi Pill | Beijing store | Clean traces | |
| 26 | RSJ03 | Renshen Jianpi Pill | Beijing store | Clean traces | |
| 27 | DD01 | Dieda Pill | Beijing store | Clean traces | |
| 28 | DD02 | Dieda Pill | Beijing store | Clean traces |
Figure 3PCR amplifications of the 28 Chinese patent medicines with DG01F/DG01R.
Note: Except for the lanes marked M (marker) and CK (positive control), the remaining 28 lanes contain PCR products from the 28 Chinese patent medicines. The order is the same as in Table 2.